润达医疗
(603108)
| 流通市值：58.89亿 | | | 总市值：58.89亿 |
| 流通股本：6.05亿 | | | 总股本：6.05亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,791,533,899.21 | 3,193,709,975.77 | 1,510,505,870.23 | 6,998,529,976.26 |
| 营业收入 | 4,791,533,899.21 | 3,193,709,975.77 | 1,510,505,870.23 | 6,998,529,976.26 |
| 二、营业总成本 | 4,751,236,151.38 | 3,128,160,636.06 | 1,504,546,302 | 7,099,474,285.35 |
| 营业成本 | 3,669,915,010.25 | 2,411,617,499.97 | 1,159,431,877.16 | 5,501,628,423.01 |
| 税金及附加 | 20,918,866.31 | 14,351,465.01 | 6,964,559.32 | 29,199,696.24 |
| 销售费用 | 484,143,322.51 | 317,345,469.9 | 156,681,465.68 | 748,601,097.65 |
| 管理费用 | 295,658,447.34 | 188,653,116.01 | 92,875,139.62 | 438,515,506.84 |
| 研发费用 | 78,926,366.71 | 53,206,049.74 | 25,928,682.72 | 108,013,762.47 |
| 财务费用 | 201,674,138.26 | 142,987,035.43 | 62,664,577.5 | 273,515,799.14 |
| 其中:利息费用 | 193,045,775.53 | 137,691,293.12 | 60,939,111.53 | 278,931,171.45 |
| 其中:利息收入 | 3,299,291.29 | 2,290,369.87 | 1,488,229.02 | 10,980,948.03 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 24,069,238.16 | 24,478,851.52 | 12,478,846.42 | 20,794,519.81 |
| 资产处置收益 | -2,077,228.45 | -2,146,048.92 | -1,481,788.22 | 3,119,148.21 |
| 资产减值损失(新) | -776,976.66 | -913,179.76 | -266,653.6 | -208,737,137.88 |
| 信用减值损失(新) | -105,192,050.53 | -91,770,284.36 | -54,742,104.55 | -196,535,945.86 |
| 其他收益 | 10,164,870.71 | 5,354,034.91 | 2,685,984.03 | 32,047,685.39 |
| 四、营业利润 | -33,514,398.94 | 552,713.1 | -35,366,147.69 | -450,256,039.42 |
| 加:营业外收入 | 621,754.49 | 189,192.18 | 178,091.31 | 5,853,029.53 |
| 减:营业外支出 | 22,294,034.82 | 11,268,276.34 | 843,523.79 | 16,234,218.1 |
| 五、利润总额 | -55,186,679.27 | -10,526,371.06 | -36,031,580.17 | -460,637,227.99 |
| 减:所得税费用 | 92,408,462.94 | 50,894,895.1 | 9,942,365.08 | 57,513,652.47 |
| 六、净利润 | -147,595,142.21 | -61,421,266.16 | -45,973,945.25 | -518,150,880.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -147,595,142.21 | -61,421,266.16 | -45,973,945.25 | -518,150,880.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -173,258,140.78 | -87,866,991.37 | -53,561,218.35 | -548,393,978.51 |
| 少数股东损益 | 25,662,998.57 | 26,445,725.21 | 7,587,273.1 | 30,243,098.05 |
| 扣除非经常损益后的净利润 | -160,709,341.53 | -80,674,008.41 | -53,161,947.11 | -565,822,548.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.29 | -0.15 | -0.09 | -0.91 |
| (二)稀释每股收益 | -0.29 | -0.15 | -0.09 | -0.91 |
| 八、其他综合收益 | 3,890,717.06 | 3,066,687.42 | 1,343,539.1 | -10,279,338.19 |
| 归属于母公司股东的其他综合收益 | 3,654,151.18 | 2,866,084.32 | 1,251,318.78 | -9,811,024.62 |
| 九、综合收益总额 | -143,704,425.15 | -58,354,578.74 | -44,630,406.15 | -528,430,218.65 |
| 归属于母公司股东的综合收益总额 | -169,603,989.6 | -85,000,907.05 | -52,309,899.57 | -558,205,003.13 |
| 归属于少数股东的综合收益总额 | 25,899,564.45 | 26,646,328.31 | 7,679,493.42 | 29,774,784.48 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |